Pfizer Inc. (PFE) EBITDA Margin: 24.12%
Is Pfizer Inc.’s EBITDA margin high or low?
Pfizer Inc.'s EBITDA margin of 24.12% is 19% below its 5-year average of 29.84%, around the middle of its 5-year range (16.05%–40.90%).
The EBITDA margin for Pfizer Inc. (PFE) is 24.12% as of Tuesday, June 9, 2026. It is below its 12-month average by 8.31% (26.30%).
PFE EBITDA Margin Chart
PFE Average EBITDA Margin Chart
PFE Current vs Average EBITDA Margin Chart
PFE EBITDA Margin Metrics
EBITDA MARGIN
24.12%
EBITDA MARGIN AVG TTM
26.30%
EBITDA MARGIN AVG 3Y
27.39%
EBITDA MARGIN AVG 5Y
29.84%
EBITDA MARGIN AVG 10Y
32.68%
EBITDA MARGIN AVG 15Y
34.16%
EBITDA MARGIN AVG 20Y
34.14%
CURRENT VS TTM AVG
-8.31%
CURRENT VS 3Y AVG
-11.94%
CURRENT VS 5Y AVG
-19.18%
CURRENT VS 10Y AVG
-26.19%
CURRENT VS 15Y AVG
-29.39%
CURRENT VS 20Y AVG
-29.35%
PFE Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | — | 24.12% | 26.30% | 27.39% | 29.84% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 35.99% | 34.83% | 32.83% | 33.18% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 46.12% | 30.77% | 33.17% | 31.82% |
| Abbott Laboratories (ABT) | $158.94B | 26.06% | 25.95% | 26.39% | 26.63% |
| Danaher Corporation (DHR) | $133.37B | 28.27% | 29.38% | 31.44% | 31.51% |
| CVS Health Corporation (CVS) | $123.84B | 2.45% | 3.06% | 3.76% | 4.57% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 30.18% | 18.37% | 30.35% | 29.39% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 41.14% | 22.77% | 35.47% | 38.89% |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 25.73% | 26.63% | 26.49% | 27.97% |
| Amgen Inc. (AMGN) | $185.96B | 43.12% | 41.54% | 45.45% | 46.07% |
Margin Comparison
Gross Margin
70.3%
EBITDA Margin
24.1%
Operating Margin
24.7%
Net Margin
12.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Pfizer Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Pfizer Inc. (PFE)?
- The EBITDA margin for PFE stock is 24.12%.
- Is Pfizer Inc.'s EBITDA margin high or low?
- Pfizer Inc.'s EBITDA margin of 24.12% is 19% below its 5-year average of 29.84%, around the middle of its 5-year range (16.05%–40.90%).
- What is the TTM average EBITDA margin for Pfizer Inc. (PFE)?
- The TTM average EBITDA margin for PFE stock is 26.30%.
- What is the 3Y average EBITDA margin for Pfizer Inc. (PFE)?
- The 3Y average EBITDA margin for PFE stock is 27.39%.
- What is the 5Y average EBITDA margin for Pfizer Inc. (PFE)?
- The 5Y average EBITDA margin for PFE stock is 29.84%.
- What is the 10Y average EBITDA margin for Pfizer Inc. (PFE)?
- The 10Y average EBITDA margin for PFE stock is 32.68%.
- What is the 15Y average EBITDA margin for Pfizer Inc. (PFE)?
- The 15Y average EBITDA margin for PFE stock is 34.16%.
- What is the 20Y average EBITDA margin for Pfizer Inc. (PFE)?
- The 20Y average EBITDA margin for PFE stock is 34.14%.
Pfizer Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 24.12% |
| 2024-12-31 | 28.49% |
| 2023-12-31 | 16.05% |
| 2022-12-31 | 40.90% |
| 2021-12-31 | 37.88% |
| 2020-12-31 | 31.62% |
| 2019-12-31 | 45.79% |
| 2018-12-31 | 36.51% |
| 2017-12-31 | 37.77% |
| 2016-12-31 | 28.95% |
| 2015-12-31 | 31.36% |
| 2014-12-31 | 38.58% |
| 2013-12-31 | 45.63% |
| 2012-12-31 | 37.36% |
| 2011-12-31 | 36.35% |
| 2010-12-31 | 29.18% |
| 2009-12-31 | 33.63% |
| 2008-12-31 | 31.68% |
| 2007-12-31 | 30.72% |
| 2006-12-31 | 38.88% |
| 2005-12-31 | 35.54% |
| 2004-12-31 | 37.03% |
| 2003-12-31 | 31.84% |
| 2002-12-31 | 40.95% |
| 2001-12-31 | 35.92% |
| 2000-12-31 | 32.25% |
| 1999-12-31 | 48.55% |
| 1998-12-31 | 45.39% |
| 1997-12-31 | 28.00% |
| 1996-12-31 | 27.44% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla